Christopher John McGann
Physician in Salt Lake City, UT
License number
Utah 336046-8905
Issued Date
Mar 3, 1999
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician/Surgeon CS (Schedule 2-5)
Address
Address
Salt Lake City, UT
Personal information
See more information about Christopher John McGann at radaris.comName
Address
Phone
1522 Michigan Ave, Salt Lake Cty, UT 84105
440 D St, Salt Lake City, UT 84103
1525 2100, Salt Lake City, UT 84119
1522 Michigan Ave, Salt Lake Cty, UT 84105
Professional information
Therapeutic Success Prediction For Atrial Fibrillation
US Patent:
2010016, Jun 24, 2010
Filed:
Dec 24, 2008
Appl. No.:
12/344164
Inventors:
Nassir F. Marrouche - Park City UT, US
Rob Macleod - Salt Lake City UT, US
Eugene Kholmovski - Salt Lake City UT, US
Christopher McGann - Salt Lake City UT, US
Joshua Blauer - Bountiful UT, US
Troy Badger - Midvale UT, US
Robert Sillman Oakes - Centerville UT, US
Nathan Burgon - Sandy UT, US
Rob Macleod - Salt Lake City UT, US
Eugene Kholmovski - Salt Lake City UT, US
Christopher McGann - Salt Lake City UT, US
Joshua Blauer - Bountiful UT, US
Troy Badger - Midvale UT, US
Robert Sillman Oakes - Centerville UT, US
Nathan Burgon - Sandy UT, US
International Classification:
A61B 5/055, A61B 5/02
US Classification:
600410, 600508
Abstract:
Certain embodiments of the invention provide methods of assessing a patient's risk for atrial fibrillation (AF) recurrence after receiving treatment with an AF treatment modality, that include determining, from left atrium (LA) tissue image data of a patient, a level of a parameter that is positively proportional to an amount of unhealthy tissue in a wall of the LA of the patient; and outputting, to an output device, an indicator of a comparison between (i) the determined level and (ii) a first threshold level of the parameter, the first threshold level derived from LA tissue image data of at least one other patient, who experienced an AF recurrence after treatment with the AF treatment modality. In certain embodiments, levels of the parameter equal to or greater than the first threshold level are indicative of a significant risk of AF recurrence after treatment with the AF treatment modality.
Christopher John McGann, Salt Lake City UT
Specialties:
Cardiologist
Address:
50 N Medical Dr, Salt Lake City, UT 84132
440 D St, Salt Lake City, UT 84103
440 D St, Salt Lake City, UT 84103
Education:
University of Virginia, School of Medicine - Doctor of Medicine
University Health Care - Fellowship - Cardiology
University Health Care - Fellowship - Cardiology
Board certifications:
American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Therapeutic Outcome Assessment For Atrial Fibrillation
US Patent:
2010016, Jun 24, 2010
Filed:
Dec 24, 2008
Appl. No.:
12/344169
Inventors:
Nassir F. Marrouche - Park City UT, US
Rob Macleod - Salt Lake City UT, US
Eugene Kholmovski - Salt Lake City UT, US
Christopher McGann - Salt Lake City UT, US
Joshua Blauer - Bountiful UT, US
Troy Badger - Midvale UT, US
Robert Sillman Oakes - Centerville UT, US
Nathan Burgon - Sandy UT, US
Rob Macleod - Salt Lake City UT, US
Eugene Kholmovski - Salt Lake City UT, US
Christopher McGann - Salt Lake City UT, US
Joshua Blauer - Bountiful UT, US
Troy Badger - Midvale UT, US
Robert Sillman Oakes - Centerville UT, US
Nathan Burgon - Sandy UT, US
International Classification:
A61B 5/055, A61B 6/00, A61B 5/02
US Classification:
600420, 600431, 600508, 600407
Abstract:
Certain embodiments provide a method of assessing an outcome of an ablative atrial fibrillation (AF) treatment modality administered to a patient, the method including: determining, from left atrium (LA) tissue image data of a subject patient that has undergone an ablative AF treatment with the modality, at least one of: a level of a parameter that is positively proportional or negatively proportional to an amount of ablated tissue in a wall of the LA of the subject patient; and a spatial distribution, in the LA wall, of a variable indicative of ablated LA tissue; and outputting, to an output device, a machine-readable indicator of at least one of: (i) a comparison between the determined level and a threshold level of the parameter; and (ii) a map of the spatial distribution.
Christopher Mcgann, Salt Lake City UT
Work:
Uumc Cardiology
50 N Medical Dr, Salt Lake City, UT 84132 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148 Intermountain Healthcare
8Th Ave, Salt Lake City, UT 84143
50 N Medical Dr, Salt Lake City, UT 84132 Va Salt Lake City Health Care System
500 Foothill Dr, Salt Lake City, UT 84148 Intermountain Healthcare
8Th Ave, Salt Lake City, UT 84143
Stroke Risk Assessment
US Patent:
2010029, Nov 25, 2010
Filed:
May 20, 2010
Appl. No.:
12/784487
Inventors:
Nassir F. Marrouche - Park City UT, US
Rob Macleod - Salt Lake City UT, US
Eugueni Kholmovski - Salt Lake City UT, US
Christopher McGann - Salt Lake City UT, US
Joshua Blauer - Bountiful UT, US
Troy Badger - Midvale UT, US
Robert Sillman Oakes - Centerville UT, US
Nathan Burgon - Sandy UT, US
Marcos Daccarett - Salt Lake City UT, US
Rob Macleod - Salt Lake City UT, US
Eugueni Kholmovski - Salt Lake City UT, US
Christopher McGann - Salt Lake City UT, US
Joshua Blauer - Bountiful UT, US
Troy Badger - Midvale UT, US
Robert Sillman Oakes - Centerville UT, US
Nathan Burgon - Sandy UT, US
Marcos Daccarett - Salt Lake City UT, US
International Classification:
A61B 5/055, A61B 5/00, A61B 6/00
US Classification:
600420, 600300, 600431
Abstract:
Certain embodiments provide a method of assessing a risk of thromboembolic stroke in a patient. The method comprises acquiring image data and determining an indicator of a degree of fibrosis of a patient's left atrium (LA) based on the image data. The method also comprises estimating a level of risk of thromboembolic stroke of the patient based on the indicator.